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ABSTRACT 
Monoclonal gammopathy of undetermined significance (MGUS) occurs in 3-7% of the elderly 
population, with higher prevalence in renal failure patients, and is associated with a 25-fold 
increased lifetime risk for plasma cell myeloma (PCM), also known as multiple myeloma.    
Using the California State Inpatient, Emergency Department, and Ambulatory Surgery Databases 
components of the Healthcare Cost and Utilization Project (HCUP), we sought to determine if 
patients with MGUS who undergo solid organ allograft (n=22,062) are at increased adjusted 
relative risk (aRR) for hematological malignancy and other complications.  Among solid organ 
transplant patients, patients with preexisting MGUS had higher aRR of PCM (aRR 19.46; 95%CI 
7.05, 53.73; p<0.001), venous thromboembolic events (aRR 1.66; 95%CI 1.15, 2.41; p=0.007), 
and infection (aRR 1.24; 95%CI 1.06, 1.45; p=0.007). However, when comparing MGUS 
patients with and without solid organ transplant, there was decreased aRR for PCM with 
transplant (aRR 0.34; 95%CI 0.13, 0.88; p=0.027), and increased venous thromboembolic events 
(aRR 2.33; 95%CI 1.58, 3.44; p<0.001) and infectious risks, (aRR 1.44; 95%CI 1.23, 1.70; 
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p<0.001).  While MGUS increased the risk of PCM overall following solid organ 
transplantation, there was lower risk of PCM development compared to MGUS patients who did 
not receive a transplant.  MGUS should not preclude solid organ transplant.INTRODUCTION 
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic 
precancerous condition that can progress to plasma cell myeloma (PCM), also known as multiple 
myeloma, or other hematologic malignancy. MGUS affects approximately 3% of people older 
than 50 years and 5% of those over 70 years of age [1]. This disorder is defined by the presence 
of a serum monoclonal protein at a concentration < 3 g/dL, a bone marrow examination with < 
10% clonal plasma cells (if performed), and the absence of end-organ damage (anemia, 
hypercalcemia, lytic bone lesions, renal insufficiency and hyperviscosity) related to the 
monoclonal protein. Recent studies have shown that PCM is almost always preceded by a plasma 
cell disorder, most commonly MGUS [2], and the rate of progression from MGUS to PCM in the 
general population is predicted to be roughly 1% per year [3]. MGUS also increases the risk of 
developing PCM approximately 25-fold [4]. In addition, MGUS has been shown to increase the 
risk of other complications, including infection, venous thromboembolism (VTE), and skeletal-
related events (SRE) such as osteoporosis and fracture [5-14].  
METHODS 
Long term data regarding patients affected by preexisting MGUS who undergo solid 
organ transplant are scarce.  Solid organ transplant requires long-term use of immunosuppression 
post-engraftment, which is associated with many risks overlapping those described above, 
including hematologic malignancies and post-transplant lymphoproliferative disease (PTLD), 
opportunistic infections, SRE and VTE.  MGUS-affected patients usually are not excluded from 
transplantation; however, data on long-term outcomes are lacking and limited to single 
institution studies with relatively small patient numbers [15-17].  We hypothesized that patients 
with the precancerous condition, MGUS, are at heightened risk for these post-transplant 
complications. 
We utilized the 2005-2011 California State Inpatient Database (SID), State Emergency 
Department Database (SEDD), and State Ambulatory Surgery Database (SASD). These 
databases are part of the Healthcare Cost and Utilization Project (HCUP), sponsored by the 
Department of Health and Human Services, Agency for Healthcare Research and Quality. These 
databases include data from patients discharged from all non-federally funded community 
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hospitals in California, including both not-for-profit and investor-owned hospitals, as well as 
hospitals run by the state and local governments.  Federally-run hospitals such as those run by 
Veterans Affairs or the Indian Health Service are not included, none of which are transplant 
centers in California.  The California HCUP databases include a synthetic patient identifier that 
can be used to track individuals’ utilization of care over the study period and across the 
emergency department, inpatient hospital, and ambulatory surgery settings. The SID includes 
over 100 variables including principal and secondary diagnoses and procedures, admission and 
discharge status, patient demographics characteristics (e.g., sex, age, and race), expected 
payment source, total charges, length of stay, and hospital characteristics (e.g. location, teaching 
status, and bed size). A complete list of variables is available in the SID data documentation 
online [18]. This study was reviewed and approved by the Institutional Review Board (IRB 
protocol #EM-14-30). 
The study population includes patients undergoing solid organ transplant as defined by 
ICD-9-CM procedure codes (Supplemental Table). The main exposure of interest was MGUS, 
defined using ICD-9-CM diagnosis code 273.1. We searched patient records with diagnosis 
codes indicating MGUS on the same day or prior to solid organ transplant surgery.  The primary 
outcomes of interest were morbidity and complications as defined by ICD-9-CM diagnosis codes 
in patient records after solid organ allograft.  The outcomes of major interest were PCM, 
lymphoma, PTLD, opportunistic infection, VTE, and SRE.  Infections included bacteremia, 
viremia, urinary tract infection, Clostridium difficile-associated diarrhea, endocarditis, 
pneumonia, influenza, and osteomyelitis.  As a secondary analysis, we sought to investigate the 
association of solid organ transplant and poor outcomes among people that had MGUS. Here, the 
study population included any person with a diagnosis code of MGUS during the study period. 
The main effect was solid organ transplant occurring on the same date or after the first diagnosis 
of MGUS. 
We conducted a descriptive analysis for all variables in our study. Comparisons between 
affected and non-affected subjects, MGUS(+) and MGUS(-), respectively, were made using 
Fisher’s exact test for categorical variables, and Student’s t-test for continuous variables.  To 
protect patient confidentiality, the data use agreement from HCUP required that cells with 
nonzero counts less than 11 cannot be reported.  Therefore, in some cases, we report the data as 
“≤10,” rather than provide the exact cell count. 
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We used modified Poisson regression to model complications in MGUS(+) versus 
MGUS(-) transplant patients to produce risk ratios with robust confidence intervals [19]. To 
adjust for patient demographics, insurance status, and comorbidities we included a propensity 
score as a covariate in the Poisson regression models [20].  The propensity score is defined as the 
predicted probability of having MGUS conditional on each patient’s baseline characteristics [21]. 
We calculated the propensity score using logistic regression with MGUS as the outcome and 
patient age, race, sex, count of all Elixhauser comorbidities, insurance, and year of transplant as 
the covariates. The Elixhauser comorbidity measure includes 30 comorbid conditions defined 
through secondary ICD-9-CM codes [22].  We also included specific comorbid conditions in the 
propensity score model if the frequency was greater than five cases in each group. The 
conditions included were hypertension, diabetes, hypothyroidism, anemia deficiency, electrolyte 
disorders, renal failure, and liver disease. Models were not fit for PTLD and lymphoma as no 
patients in the MGUS+ group experienced these outcomes. All of the above analysis was 
repeated in the MGUS population comparing solid organ transplant (+) vs solid organ transplant 
(-). All analyses were conducted on SAS version 9.3 for Unix (SAS Institute, Cary, NC).   
RESULTS 
Of the 24,358,669 patients in the California State Inpatient, Emergency, and Ambulatory 
Database from 2005-2011, we identified 22,062 solid organ transplant patients.  Of these 
patients, 72 were found to be MGUS(+) prior to solid organ transplant.  MGUS was not 
documented in the remaining 21,990 transplant patients prior to solid organ transplant.  
Demographic characteristics of solid organ transplant patients are shown in Table 1.  Median age 
for the MGUS(+) group was somewhat older (61.5 years, versus 51 years for the MGUS (-) 
group, p<0.001).  MGUS(+) solid organ transplant patients had significantly fewer comorbidities 
than MGUS(-) patients.  As there were a number of demographic differences between the 
groups, propensity score adjusted risk ratios were utilized for further analysis. 
Table 2 shows the outcomes of interest for solid organ transplant recipients according to 
MGUS status.  There were ≤10 cases of PCM reported in the MGUS(+) group and 37 in the 
MGUS(-) group.  Among solid organ transplant patients, those MGUS(+) patients had a nearly 
20-fold higher risk of developing PCM compared to MGUS(-) (Table 3), with a propensity score 
adjusted risk ratio of 19.46 (95%CI 7.05, 53.73).  While there were no cases of PTLD or 
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lymphoma in the MGUS(+) group, there were 161 and 193 cases, respectively, in the MGUS(-) 
group.  
For the 72 patients in the MGUS(+) group, we identified a significantly higher incidence 
of several complications compared to the MGUS(-) group.  Pulmonary embolism, VTEs, SREs, 
bacteremia, urinary tract infection, Clostridium difficle infection, and pneumonia were found to 
occur more frequently in the MGUS(+) group when compared to the MGUS(-) group (Table 2). 
Among solid organ transplant patients, MGUS(+) patients had a higher risk of developing VTE, 
SRE, and infection compared to MGUS(-) patients, with propensity adjusted risk ratios of 1.66 
(95%CI 1.15, 2.41), 1.56 (95%CI 1.03, 2.37), and 1.24 (95%CI 1.06, 1.45), respectively (Table 
3).  In-hospital death risk was significantly increased for MGUS(+) solid organ transplant 
patients, compared to those unaffected by MGUS, with a propensity score adjusted relative risk 
of 1.58 (95% CI 1.18, 2.11). 
While risk for complications or in-hospital death seemed higher for MGUS(+) solid 
organ transplant recipients, these data did not address the risk for similar MGUS(+) patients 
without transplant.  First, we sought to determine the risk for these outcomes amongst all 
MGUS(+) patients with and without solid organ transplant.  Utilizing propensity-score 
adjustment, we next sought to determine the risk for these outcomes in MGUS(+) patients 
according to transplant status.  Amongst MGUS(+) patients, there were ≤ 10 cases of PCM in 
those receiving solid organ transplant, versus 1,631 for those without transplant (Table 4).  In 
fact, PCM risk was decreased with solid organ transplant, with a propensity-adjusted risk ratio of 
0.34 (95%CI 0.13, 0.88) for progression of MGUS to PCM.  There were no reported PTLD or 
lymphoma cases in the transplanted MGUS(+) patients, although sample size was somewhat 
small.    There were increased infectious and VTE events in the transplant group, with propensity 
score adjusted risk ratios of 1.44 (95%CI 1.23, 1.70) and 2.33 (95%CI 1.58, 3.44), respectively 
(Tables 4-5).   SRE risk was not significantly different once adjusted for propensity score. 
Unadjusted in-hospital deaths were not significantly different for MGUS(+) patients with solid 
organ transplants, although significance was uncovered once the cohort was adjusted by 
propensity score, with an adjusted risk ratio of 1.47 (95% CI 1.09, 1.98) for those MGUS 
patients with an allograft. 
 
DISCUSSION 
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Solid organ transplant recipients require long-term immunosuppression post-transplant 
that may lead to significant complications.  We undertook this analysis of HCUP component 
databases to ascertain whether solid organ transplant recipients affected by a common disorder, 
MGUS, would be at heightened risk for serious complications that are shared by patients 
undergoing transplant immunosuppression and by patients with MGUS.  Unlike the National 
Inpatient Sample, the California SID has the advantage of capturing data for a given patient at 
every California hospital, rather than just the data captured and submitted by the transplant 
center to the Organ Procurement and Transplantation Network (OPTN), and additionally 
contains diagnoses and procedures that are unavailable to the OPTN-based sources [23].  While 
those patients with preexisting MGUS experienced greater overall risks after solid organ 
transplant, the degree of increased risk suggests that these patients should not be excluded from 
solid organ transplant options. 
Overall PTLD risk for solid organ transplant patients varies by organ-type and 
immunosuppression protocol.  The risk is typically cited to be about 0.4% at one year for kidney 
transplant patients [24], but does not appear to be of high concern in this particular cohort of 
patients, with PTLD found in only 0.7% of the MGUS(-) patients and none of the MGUS(+) 
patients.  On the other hand, compared to solid organ transplant patients without preexisting 
MGUS, our data demonstrated that solid organ transplant patients with preexisting MGUS had a 
significantly higher risk of VTE, SRE, and a variety of infections, including bacteremias, urinary 
tract infections, Clostridium difficile-associated diarrhea, and infectious pneumonia. 
Consistent with other patient populations, we report that solid organ transplant patients 
with preexisting MGUS are also more likely to develop PCM than those without preexisting 
MGUS; however, this risk is similar to—or perhaps even lower than—that historically attributed 
to MGUS in patients who have not undergone transplant.  Literature addressing PCM in MGUS 
patients following solid organ transplant is scarce and conflicting.  Safadi et al [25] reported 4 of 
7 multiple myeloma patients with kidney transplants demonstrated pre-existing MGUS.  In a 
retrospective review of 1,593 solid organ transplant patients, Jimenez-Zipeda et al [26] reported 
that none of 34 patients with preexisting MGUS had progression to PCM, amyloid, or 
lymphoma, and they noted no association between preexisting MGUS and PTLD. In a slightly 
larger retrospective review of 3,518 kidney transplant patients that included 23 patients with 
preexisting MGUS, 4 (17.4%) patients developed a hematologic malignancy (2 smoldering PCM 
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and 2 PTLD) [17]. Another small case series in which 5 transplant patients with preexisting 
MGUS were followed showed 2 patients developed smoldering PCM after transplant [27], with 
other small studies reporting similar findings [15, 28].  In contrast, we found a somewhat 
reduced risk for PCM for patients with preexisting MGUS and solid organ transplant.  Previous 
studies tended to be single center and often included patients who developed MGUS post-
transplant.  Interestingly, in a study of US veterans, MGUS patients with immune-mediated 
conditions, including autoimmunity, inflammatory disorders, and certain infectious disorders, 
were found to have increased risk of MGUS progression to PCM [29].  It is certainly possible 
that solid-organ transplant-related immunosuppression alters the likelihood of MGUS 
progression to PCM. 
This study has limitations.  There are inherent shortcomings in large retrospective 
database studies, including inconsistencies in-patient follow up, reporting, and coding practices. 
As the databases relied upon hospitalization or admission to an ambulatory surgery facility or 
emergency department for entry, subjects receiving care outside of these settings are not 
represented.  Use of other large observational databases, however, suggests that many of the 
observations are consistent with randomized clinical trials and expert opinion [30-31].  In 
addition, as MGUS is present in about 3% of people greater than age 50 years [1], it is almost 
certainly underrepresented in this database.  Outcomes of MGUS are variable, and a risk 
stratification system has been developed to predict the risk of progression from MGUS to PCM 
based on the amount of monoclonal protein, immunoglobulin type, and the serum free light chain 
ratio [32].  Unfortunately, these databases lack the data granularity to stratify patients based on 
such differentiation.  Similarly, while diagnostic criteria for monoclonal gammopathy of renal 
significance has been proposed in 2012 [33], the date range from the database we utilized was 
prior to this proposed term and, in addition, that diagnostic terminology does not have an ICD-9 
code independent from the MGUS code [34-35].   Similarly, the database does not include 
information on induction and maintenance immunosuppression use, which given the variability 
in practice and potential modifications in MGUS patients, could impact outcomes.  Furthermore, 
despite the large sample size, the number of transplanted patients with MGUS and event rates 
were relatively low, thereby limiting statistical power.  Sample size also prevented meaningful 
analysis of organ-specific outcomes—which is pertinent for kidney transplantation, as MGUS is 
more common in this population.  While we adjusted by propensity score to accommodate 
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different levels of comorbidity to minimize selection bias, we can only control for known 
confounders that we could measure in our data.  Further, the small number of cases in the MGUS 
group prevented us from direct adjustment of particular comorbidities, which may better control 
for patient differences. Finally, meaningful post-transplant survival analysis is not feasible with 
this dataset, as in-hospital mortality is biased towards patients requiring more frequent 
admission.   
In conclusion, patients with preexisting MGUS who undergo solid organ transplantation 
have higher risks compared to MGUS-unaffected patients for developing complications such as 
PCM, VTE, SRE, and opportunistic infections.  However, solid organ transplant in patients with 
preexisting MGUS does not appear to further increase the risk of progression to PCM in patients 
with solid organ transplant, nor do PTLD and lymphoma risks seem to increase.  In contrast, 
solid organ transplant patients with preexisting MGUS are at higher risk for VTE, SRE, and 
infection, suggesting that closer monitoring for such events is warranted.  While MGUS is a risk 
factor for future PCM, it should not preclude solid organ transplantation. 
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of Cleveland (UL1TR000439) from the National Center for Advancing Translational Sciences 
(NCATS) component of the National Institutes of Health and NIH roadmap for Medical 
Research, and by a grant from the National Cancer Institute (K12CA076917).  Its contents are 
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 Table 1: Characteristics of Solid Organ Transplant Patients.  
 
 MGUS (+) 
N=72 
MGUS (-) 
N=21,990 
p 
 Age, years   
     Median (IQR) 61.5 (52 – 66.5)  51 (37 – 60) 
     Mean (std dev) 58.5 (11.6) 47.1 (17.3) <0.001 
 Sex  0.549 
     Male 41 (56.9%)  13,390 (60.9%) 
     Female 30 (41.7%)  8,493 (38.6%) 
 Race  0.009 
     Black/Other 14 (19.4%)  5,265 (23.9%) 
     Hispanic 13 (18.1%)  6,480 (29.5%)  
     White 39 (54.2%)  9,535 (43.4%) 
 Insurance  0.495 
     Private 31 (43.1%)  8,241 (37.5%) 
     Public 40 (55.6%)  13,089 (59.5%) 
 Comorbidities  <0.001 
     None 15 (20.8%)  2,960 (13.5%) 
     1 to 2 19 (26.4%)  9,899 (45.0%) 
     3 to 4 20 (27.7%)  6,377 (29.0%) 
     Five or more 18 (25.0%)  2,754 (12.5%) 
 Transplant type*  0.228 
          Kidney 45 (61.6%)  14,031 (63.8%) 
          Liver 13 (17.8%)  5,064 (23.0%) 
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≤10* 
          Lung   1,275 (5.8%) 
≤10* 
          Heart/lung   64 (0.3%) 
          Heart 13 (17.8%)  1,866 (8.5%) 
Of the 22,062 solid organ transplant patients identified in the database, 108 patients had 
missing sex data and 716 patients had missing race data.  
 
*Frequencies ≤10 are reported 
as such per the data use agreement.  
 
 
 
Table 2: Outcomes in Solid Organ Transplant Patients 
 
 
 
Outcome 
MGUS (+) 
N=72 
MGUS (–) 
N=21,990 
 
p 
PTLD 0 161 (0.7%) 0.999 
PCM ≤10* 37 (0.2%) <0.001 
Lymphoma 0 193(0.9%) 0.999 
VTE 20 (27.7%) 3,202 (14.6%) 0.004 
          Pulmonary embolism ≤10* 624 (2.8%) 0.017 
          Venous embolism/thrombosis 16 (22.2%) 2,920 (13.3%) 0.035 
SRE 18 (25%) 2,320 (10.5%)  <0.001 
Infection 50 (69.4%) 11,612 (52.8%) 0.006 
          Bacteremia 15 (20.8%) 2,029 (9.2%) 0.003 
          Viremia ≤10* 335 (1.5%) 0.999 
          Urinary tract infection 36 (50%) 7,076 (32.2%) 0.002 
          C. difficle-associated diarrhea 15 (20.8%) 1,942 (8.8%) 0.001 
          Endocarditis 0 356 (1.6%) 0.634 
          Pneumonia 30 (41.7%) 6,159 (28.1%) 0.012 
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          Influenza 0 516 (2.4%) 0.419 
          Osteomylitis ≤10* 650 (2.9%) 0.999 
In-hospital death 29 (40.3%) 4,449 (20.2%) <0.001 
*Frequencies ≤10 are reported as such per the data use agreement.  
 
Table 3: Outcomes in Solid Organ Transplant Patients  
 
 
 
 
 
 
 
R
isk ratio (RR) represents the increased risk of each outcome among those with MGUS 
compared to those without MGUS among solid organ transplant patients. Risk ratio for 
PTLD and Lymphoma were incalculable due to zero instances in the MGUS(+) group. The 
risk ratio and 95% confidence interval was obtained from modified Poisson regression 
models.  
 
Table 4: Outcomes in MGUS Patients 
 
 
 
Outcome 
 Transplant 
Recipients 
N=72 
Non-transplant 
Patients 
N=12,060 
 
p-value 
PTLD 0 n/a n/a 
PCM ≤10* 1,631 (13.5%) 0.055 
Outcome  Unadjusted Risk 
Ratio (95% CI) 
p Propensity score 
adjusted Risk Ratio 
(95% CI) 
p 
PCM  31.11 (12.62, 76.71) <0.001 19.46 (7.05, 53.73) <0.001 
VTE  1.80 (1.24, 2.60) 0.002 1.66 (1.15, 2.41) 0.007 
SRE  2.23 (1.50, 3.33) <0.001 1.56 (1.03, 2.37) 0.036 
Infection  1.24 (1.06, 1.44) 0.006 1.24 (1.06, 1.45) 0.007 
In-hospital 
death 
1.88 (1.42, 2.49) <0.001 1.58 (1.18, 2.11) 0.002 
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Lymphoma 0 591(4.9%) 0.051 
VTE 20 (27.7%) 1,257 (10.4%) <0.001 
          Pulmonary embolism ≤10* 444 (3.7%) 0.050 
          Venous embolism/thrombosis 16 (22.2%) 1,035 (8.6%) <0.001 
SRE 18 (25%) 3,530 (29.2%)  0.516 
Infection 50 (69.4%) 6,806 (56.4%) 0.031 
          Bacteremia 15 (20.8%) 534 (4.4%) <0.001 
          Viremia ≤10* ≤10* 0.052 
          Urinary tract infection 36 (50%) 4,347 (36.0%) 0.019 
          Clostridium difficle 15 (20.8%) 852 (7.1%) <0.001 
          Endocarditis 0 204(1.7%) 0.636 
          Pneumonia 30 (41.7%) 4,184 (34.7%) 0.217 
          Influenza 0 99 (0.8%) 0.999 
          Osteomylitis ≤10* 383 (3.2%) 0.999 
In-hospital death 29 3,942 0.207 
*Frequencies ≤10 are reported as such per the data use agreement.  
 
 
Table 5: Risk of outcomes among MGUS patients by transplant status 
 
 
 
 
 
 
Outcome  Unadjusted Risk 
Ratio (95% CI) 
p Propensity score 
adjusted Risk Ratio 
(95% CI) 
p 
PCM  0.41 (0.16, 1.06) 0.067 0.34 (0.13, 0.88) 0.027 
VTE  2.66 (1.83, 3.88) <0.001 2.33 (1.58, 3.44) <0.001 
SRE  0.85 (0.57, 1.28) 0.441 1.33 (0.87, 2.03) 0.195 
Infection  1.23 (1.05, 1.44) 0.008 1.44 (1.23, 1.70) <0.001 
In-hospital death 1.23 (0.93, 1.63) 0.147 1.47 (1.09, 1.98) 0.011 
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Risk ratio (RR) represents the increased risk of each outcome among those patients with 
MGUS comparing those with versus without solid organ transplant. Risk ratio for PTLD 
and Lymphoma were incalculable due to zero instances in the MGUS(+) group. The risk 
ratio and 95% confidence interval was obtained from modified Poisson regression models. 
 
Supplemental Table: ICD-9 Diagnosis and Procedure Codes 
 
ICD-9 Diagnosis and Procedure Codes 
Diagnosis Code 
Monoclonal paraproteinemia (MGUS) 273.1 
Multiple myeloma (or PCM) 203 
PTLD 238.77 
Lymphoma 200, 201, 202 
 Venous thromboembolism (VTE) 
          Pulmonary embolism 415.1, 416.2 
          Venous embolism and thrombosis 453 
 Skeletal related events (SRE) 
          Osteoporosis, pathologic fracture 733.0-733.1 
 Infections 
          Viremia 790.8 
          Bacteremia 790.7 
          Endocarditis 421, 424.9 
          Urinary tract infection 599.0 
          Clostridium difficile  008.45 
          Pneumonia 480-486 
          Influenza 487-488 
          Osteomyelitis 730 
 Solid organ transplant 
          Kidney 55.6 
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          Liver 50.5 
          Lung  33.5 
          Heart/lung  33.6 
          Heart 37.51 
          Pancreas 52.8 
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